

Day 1: 20th October 2021

12:30	Arrival and Registration Welcome Coffee/Tea
13:30	Introduction to GMP 2021 Symposium
13:40	<p>Session 1: Organ-On-a-Chip: towards the in vitro human twin for pharmacokinetics, pharmacodynamics and toxicology predictions Chairs : Gattacceca F. (COMPO, CRCM, Aix-Marseille-University), Parmentier Y. (Servier)</p> <p>S1.1 Tao T.P. (TissUse, Germany) Advancing PK/PD predictions with micro-physiological systems</p> <p>S1.2 Mabondzo A. (CEA, France) Modeling human blood-brain barrier from human pluripotent stem cells: importance of flow dynamics</p> <p>S1.3 Legallais C. (CNRS, France) Organ-on-chip combined with omics and PBPK : some examples</p>
Sponsor talk: Emulate and Lablogic	
15:10	Coffee break and poster session
15:40	<p>Session 2: Bioequivalence: from derisking strategies to regulatory support Chairs: Chatelut E. (Oncopole Toulouse), Nicolas O. (Sanofi), Nguyen Q. (Ipsen)</p> <p>S2.1 Concordet D. (ENVIT, France) Bioequivalences and Levothyrox</p> <p>S2.2 Konstantinidis I.L. (Novartis, Switzerland) Physiologically based pharmacokinetic modeling and simulation to support virtual bioequivalence trials in drug development</p> <p>S2.3 Garcia A. (AEMPS, Spain) Bioequivalence</p>
Sponsor talk: Solvo and Pharmetheus	
17:10	<p>Students' Poster Blitz Chairs: Troisi C. (PhD Student, Bologna university), Rachid M. (M&Y Chemical and Pharma Consulting)</p>
18:05	Cocktail sponsored by
20:30	

Day 2: 21st October 2021

08:00	Welcome Coffee/Tea
08:30	<p>Keynote speaker: Michael Zimmerman (EMBL - Medice, Germany) Identifying microbiome contributions to drug metabolism and toxicity Chair: Parmentier Y. (Servier)</p>
Sponsor talk: Cyprotex and Quotient Sciences	
09:30	Coffee break and poster session
10:00	<p>Session 3: Microbiota: Am I controlled by My Microbiota? Chairs: Barcham R. (Oroxcell), Grégoire N. (Poitiers University) Fonsi M. (Charles-River)</p> <p>S3.1 Blanquet-Diot S. (Clermont Auvergne University, France) <i>In vitro</i> gut models as efficient tools to decipher the role of human gut microbiota in drug pharmacokinetics</p> <p>S3.2 Pichon M. (CHU Poitiers, France) Challenge in exploring the human skin microbiome : new questions and/or new tools?</p> <p>S3.3 Rawadi G (Ysopia, France) Harnessing the Power of Gut Keystone Bacteria into Ground-Breaking Biotherapies</p> <p>S3.4 Levast B. (Maat Pharma, France) PK/PD challenges for gut microbiota-derived biotherapeutics in preclinical and clinical studies</p>
12:00	GMP Assemblée Générale 2021
12:45 14:00	Lunch and posters

Day 2: 21st October 2021

14:00	<p>Session 4: PK/PD challenges in the development of virus-based gene therapy and strategies to modulate the PK/PD variability of antiviral drugs Chairs: Nicolas O. (Sanofi), Courbebaisse Y. (Adocia), Nguyen Q. (Ipsen)</p> <p>S4.1 Bendjama K. (Transgene, France) Challenges in clinical pharmacodynamic assessments of cancer therapies based on viral vectors</p> <p>S4.2 Solas C. (AP-HM, INSERM, Aix-Marseille University, France) Challenges and strategies to modulate the PK/PD variability of antiviral drugs in clinical practice</p>
Sponsor talk: Simulations Plus	
15:00	Coffee break and poster session
15:30	<p>Session 5: PK challenges in vaccine development Chairs: Bain C. (Active Biomarkers), Coquerel A. (Caen University), Gattacceca F. (COMPO, CRCM, Aix-Marseille university)</p> <p>S5.1 Amiji M. (Northeastern University, USA) Vaccine formulation and delivery strategies to improve global access</p> <p>S5.2 Desert P. (Sanofi Pasteur, France) Biodistribution studies applied to vaccine modalities</p> <p>S5.3 Combadiere B. (Sorbonne University, France) Early biomarkers of immune responses: challenges in vaccine development</p>
17:00 18:00	<p>Session one step aside: Pr. Maxime Schwartz (Institut Pasteur, France) Une histoire des vaccins, de celui contre la variole à ceux contre la COVID-19 Chair: Coquerel A. (Caen University)</p>
19:30	Gala Dinner at La Baleine Blanche

Day 3: 22nd October 2021

08:30	Welcome coffee/Tea
09:00	<p>Session 6 : Personalized medicine: how far are we? Chairs: Aslanis V. (Galacto), Barberan O. (Elsevier), Grégoire N. (Poitiers University), Parmentier Y. (Servier)</p> <p>S6.1 Pallaud C. (Novartis, Switzerland) Title to be confirmed</p> <p>S6.2 Dayan F. (ExactCure, France) A digital twin approach in PKPD</p> <p>S6.3 Turgeon J. (TabulaRasa HealthCare, USA) Adverse drug event risk assessment by the virtual addition of drugs to patient's drug regimen</p> <p>S6.4 Rostami A. (Certara & Manchester University, UK) Anticipate the arrival & growth of precision dosing: liquid biopsy proposes a marriage to QSP/PBPK!</p>
Sponsor talk: Certara	
11:00	Coffee break
11:30	<p>Session 7: Use of pharmacokinetics/ pharmacodynamics in cell therapy Chairs: Bain C. (Active Biomarkers), Duval V. (Certara), Courbebaisse Y. (Adocia)</p> <p>S7.1 Baruchel A. (APHP, France) Toward optimizing efficacy and tolerance of CAR-T cells</p> <p>S7.2 Renard E. (INSERM & CHU Montpellier, France) Automated insulin delivery systems: how far are we from physiology?</p>
12:30	<p>Poster Awards sponsored by</p> 
12:45	Closing Remarks
12:55 14:00	Farewell lunch